发布求助
文献互助 智能选刊 最新文献

Trends in cancer最新文献

筛选
英文 中文
STEAP1: a promising target in prostate cancer therapy. STEAP1：前列腺癌治疗的一个有希望的靶点。
IF 17.5 1区 医学
Trends in cancer Pub Date : 2025-08-01 Epub Date: 2025-06-16 DOI: 10.1016/j.trecan.2025.05.007
Rohit Singh, Jon Amund Kyte
{"title":"STEAP1: a promising target in prostate cancer therapy.","authors":"Rohit Singh, Jon Amund Kyte","doi":"10.1016/j.trecan.2025.05.007","DOIUrl":"10.1016/j.trecan.2025.05.007","url":null,"abstract":"<p><p>The unmet therapeutic need in prostate cancer (PCa), a disease that remains largely incurable after metastasis, underscores the urgency for new treatments. STEAP1 (six transmembrane epithelial antigen of prostate 1) is a cell surface protein highly expressed in >85% prostate tumors but shows little to no presence in normal tissues, making it a promising candidate for targeted therapy. Here, we summarize and discuss recent findings that underscore the promising role of STEAP1 in PCa therapy.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"722-725"},"PeriodicalIF":17.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144318036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
mtDNA transfer from senescent cancer cells to MDSCs promotes immunosuppression. mtDNA从衰老癌细胞转移到MDSCs促进免疫抑制。
IF 17.5 1区 医学
Trends in cancer Pub Date : 2025-08-01 Epub Date: 2025-07-02 DOI: 10.1016/j.trecan.2025.06.010
Israel Cañadas, Takahiko Murayama, Lorenzo Galluzzi
{"title":"mtDNA transfer from senescent cancer cells to MDSCs promotes immunosuppression.","authors":"Israel Cañadas, Takahiko Murayama, Lorenzo Galluzzi","doi":"10.1016/j.trecan.2025.06.010","DOIUrl":"10.1016/j.trecan.2025.06.010","url":null,"abstract":"<p><p>Sublethal apoptotic stress causing the permeabilization of some mitochondria coupled with cytosolic mitochondrial DNA (mtDNA) accumulation is known to promote cellular senescence. Lai et al. have recently demonstrated that this may be accompanied by mtDNA release within extracellular vesicles that promote local immunosuppression via myeloid-derived suppressor cells.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"716-718"},"PeriodicalIF":17.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144561298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunocytokines and cytokine neutralization for cancer immunotherapy. 免疫细胞因子和细胞因子中和在癌症免疫治疗中的应用。
IF 17.5 1区 医学
Trends in cancer Pub Date : 2025-08-01 Epub Date: 2025-05-27 DOI: 10.1016/j.trecan.2025.04.014
Pedro Berraondo, Raquel Cuesta, Fernando Aranda, Ana Martinez-Riaño, Iñaki Eguren-Santamaria, Carlos Luri-Rey, Aline Risson, Ana Melero, Gabriel Gomis, Ignacio Melero
{"title":"Immunocytokines and cytokine neutralization for cancer immunotherapy.","authors":"Pedro Berraondo, Raquel Cuesta, Fernando Aranda, Ana Martinez-Riaño, Iñaki Eguren-Santamaria, Carlos Luri-Rey, Aline Risson, Ana Melero, Gabriel Gomis, Ignacio Melero","doi":"10.1016/j.trecan.2025.04.014","DOIUrl":"10.1016/j.trecan.2025.04.014","url":null,"abstract":"<p><p>Despite deep and growing knowledge of cytokine functions, immunotherapies based on the control of these molecules have minimally impacted cancer patient management because of limited efficacy and narrow therapeutic windows. Opportunities to enhance efficacy and mitigate side effects arise from local delivery and targeting antitumor cytokines to tumor tissue via chimeric fusion with antibodies (immunocytokines). Conversely, neutralization of protumor cytokines using antibodies, cytokine traps, or receptor antagonists offer the opportunity to increase the efficacy of conventional immunotherapy with checkpoint inhibitors while reducing their side effects. Exploiting the immunobiology of interleukin (IL)-2, IL-12, IL-15, IL-18, and IL-21 in synergistic combinations with other treatments holds promise. The antagonistic neutralization of transforming growth factor-β, tumor necrosis factor, IL-1, IL-6, and CXCR1/2 chemokines and growth differentiation factor 15 also seems to be very convenient, again as part of combination strategies.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"790-805"},"PeriodicalIF":17.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144161135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Leveraging immunologically based therapies to treat diffuse large B-cell lymphoma. 利用免疫疗法治疗弥漫性大b细胞淋巴瘤。
IF 17.5 1区 医学
Trends in cancer Pub Date : 2025-07-23 DOI: 10.1016/j.trecan.2025.06.013
Jennifer K Lue, Sean E Healton, Gilles A Salles
{"title":"Leveraging immunologically based therapies to treat diffuse large B-cell lymphoma.","authors":"Jennifer K Lue, Sean E Healton, Gilles A Salles","doi":"10.1016/j.trecan.2025.06.013","DOIUrl":"10.1016/j.trecan.2025.06.013","url":null,"abstract":"<p><p>Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous group of aggressive lymphomas driven by distinct biological pathways. Although historically divided into two major subtypes on the basis of putative cell of origin, detailed genomic analyses have revealed additional classifications with prognostic implications. Additionally, the lymphoma microenvironment adds a layer of complexity distinct from genetic subclassifications and influences disease trajectory and response to therapies. Herein, we review the emerging roles of immune-based therapies to address this complex interplay between intrinsic genetic drivers and the surrounding tumor microenvironment in DLBCL.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":""},"PeriodicalIF":17.5,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12326298/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144708994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Platelets: tailoring metastasis treatment. 血小板：转移治疗。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-07-17 DOI: 10.1016/j.trecan.2025.06.012
Vincent Mittelheisser, Cristina Liboni, Silvia Maria Grazia Trivigno, Olivier Lefebvre, Pierre H Mangin, Jacky G Goetz
{"title":"Platelets: tailoring metastasis treatment.","authors":"Vincent Mittelheisser, Cristina Liboni, Silvia Maria Grazia Trivigno, Olivier Lefebvre, Pierre H Mangin, Jacky G Goetz","doi":"10.1016/j.trecan.2025.06.012","DOIUrl":"https://doi.org/10.1016/j.trecan.2025.06.012","url":null,"abstract":"<p><p>The dreadful liaison between platelets and tumor cells was discovered half a century ago. Since then, a plethora of studies have characterized the contribution of platelets to primary tumor development, survival of circulating tumor cells in the bloodstream, and metastatic seeding and outgrowth. Yet, although these provided a deep understanding of how platelets shape cancer progression, the field suffers from a lack of additional knowledge required to design efficient therapeutic strategies. Here, we aim to summarize recent discoveries that identify new ways in which platelets shape metastasis beyond their initial intravascular role. We further discuss platelet-borne molecular targets that could represent new avenues for therapeutically targeting platelets' contribution to metastasis.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":""},"PeriodicalIF":14.3,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144668607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Time-of-day dependency of adoptive cell therapies. 过继细胞疗法的时间依赖性。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-07-15 DOI: 10.1016/j.trecan.2025.06.011
Constant Adriaan Tellinga, Roman Friedli, Federico Simonetta, Christoph Scheiermann
{"title":"Time-of-day dependency of adoptive cell therapies.","authors":"Constant Adriaan Tellinga, Roman Friedli, Federico Simonetta, Christoph Scheiermann","doi":"10.1016/j.trecan.2025.06.011","DOIUrl":"https://doi.org/10.1016/j.trecan.2025.06.011","url":null,"abstract":"<p><p>Adoptive cell therapies (ACTs), such as chimeric antigen receptor (CAR)-T cell therapy, have revolutionized cancer treatment, especially for hematological cancers. However, patient responses vary considerably. Emerging research reveals a striking influence of time of day (ToD) on ACT efficacy. Administering ACT during the early behavioral active phase enhances tumor control and reduces toxicity in preclinical models, an effect linked to the circadian clock. Latest clinical data also point to ToD effects in the cancer setting. In this opinion article we explore current insights and discuss the emerging underlying mechanisms. We propose that integrating ToD into clinical practice could represent a powerful yet easily implementable therapeutic regimen to improve efficacy and safety of ACT.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":""},"PeriodicalIF":14.3,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144650620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GDF15: from biomarker to target in cancer cachexia. GDF15：从生物标志物到癌症恶病质靶标。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-07-09 DOI: 10.1016/j.trecan.2025.06.007
Max Hüllwegen, Maximilian Kleinert, Stephan von Haehling, Andreas Fischer
{"title":"GDF15: from biomarker to target in cancer cachexia.","authors":"Max Hüllwegen, Maximilian Kleinert, Stephan von Haehling, Andreas Fischer","doi":"10.1016/j.trecan.2025.06.007","DOIUrl":"https://doi.org/10.1016/j.trecan.2025.06.007","url":null,"abstract":"<p><p>Most patients with advanced cancer suffer from cachexia, a complex metabolic disorder characterized by unintentional body weight loss that diminishes their quality of life and reduces the effectiveness of therapies. Currently, effective treatments for cachexia remain elusive. Growth differentiation factor 15 (GDF15) is a nonspecific blood biomarker of cancer, hyperemesis gravidarum, and various chronic diseases. GDF15 acts through GDNF family receptor α-like (GFRAL) receptors in the hindbrain to influence food intake, nausea, body weight, and insulin sensitivity. In this review we synthesize the current literature on the role of GDF15 in regulating metabolism and immunosuppression, and elucidate how these processes impact on cancer progression. We highlight recent clinical trials demonstrating that targeting GDF15 can overcome resistance to immunotherapy and increase physical activity, appetite, and weight gain in cancer patients.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":""},"PeriodicalIF":14.3,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144609705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IL-18 revives dysfunctional CAR-T cells. IL-18可以激活功能失调的CAR-T细胞。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-07-07 DOI: 10.1016/j.trecan.2025.06.008
Yan-Ruide Li, Yichen Zhu, Lili Yang
{"title":"IL-18 revives dysfunctional CAR-T cells.","authors":"Yan-Ruide Li, Yichen Zhu, Lili Yang","doi":"10.1016/j.trecan.2025.06.008","DOIUrl":"https://doi.org/10.1016/j.trecan.2025.06.008","url":null,"abstract":"<p><p>IL-18-armored chimeric antigen receptor (CAR)-engineered T (18.CAR-T) cells have demonstrated enhanced antitumor efficacy in lymphoma patients refractory to conventional CAR-T therapy. Unraveling the mechanisms behind this potent enhancement and mitigating associated toxicities could unlock a new era of next-generation CAR-T therapies with superior effectiveness and broader clinical impact.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":""},"PeriodicalIF":14.3,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144592443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Beyond safety: suicide systems in cell-based cancer therapies. 超越安全：细胞癌症治疗中的自杀系统。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-07-03 DOI: 10.1016/j.trecan.2025.06.003
Kok-Siong Chen, Khalid Shah
{"title":"Beyond safety: suicide systems in cell-based cancer therapies.","authors":"Kok-Siong Chen, Khalid Shah","doi":"10.1016/j.trecan.2025.06.003","DOIUrl":"https://doi.org/10.1016/j.trecan.2025.06.003","url":null,"abstract":"<p><p>Cell-based therapies are promising for treating solid tumors, but challenges like tumor heterogeneity, antigen escape, and immunosuppressive microenvironments hinder their efficacy. Inducible suicide gene systems, often viewed solely as safety mechanisms, offer an underappreciated opportunity to enhance cellular therapies. These systems, triggered by various mechanisms (prodrugs, ligands, antibodies, or small molecules), enable controlled elimination of therapeutic cells. Recent developments demonstrate that this controlled cell death, especially when inducing immunogenic cell death (ICD), can kill even resistant tumor cells and reshape the tumor microenvironment (TME) from suppressive to stimulatory. This review highlights the transformative potential of integrating these suicide systems into cell therapies, overcoming key limitations, and amplifying antitumor responses while ensuring safety.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":""},"PeriodicalIF":14.3,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144565272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The future of tumor organoids in precision therapy. 肿瘤类器官在精准治疗中的未来。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-07-01 Epub Date: 2025-04-03 DOI: 10.1016/j.trecan.2025.03.005
Seok-Young Kim, Marc van de Wetering, Hans Clevers, Karin Sanders
{"title":"The future of tumor organoids in precision therapy.","authors":"Seok-Young Kim, Marc van de Wetering, Hans Clevers, Karin Sanders","doi":"10.1016/j.trecan.2025.03.005","DOIUrl":"10.1016/j.trecan.2025.03.005","url":null,"abstract":"<p><p>Tumoroids are cultures of patient-derived tumor cells, which are grown in 3D in the presence of an extracellular matrix extract and specific growth factors. Tumoroids can be generated from adult as well as pediatric cancers, including epithelial cancers, sarcomas, and brain cancers. Tumoroids retain multi-omic characteristics of their corresponding tumor and recapitulate interpatient and intratumor heterogeneity. Retrospective and prospective studies have demonstrated that tumoroids predict patient responses to anticancer therapies, making them a promising tool for precision oncology. However, several challenges remain before tumoroids can be fully integrated into clinical decision-making, including success rates of tumoroid establishment and turnaround times. This review discusses the current advances, challenges, and future directions of tumoroid-based models in cancer research and precision therapy.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"665-675"},"PeriodicalIF":14.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143789244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信